health news today obesity drugs glp-1 Use of to Treat Overweight or Increased 587 Percent from 2019 to 2024, According to New FAIR Study Commentary: New obesity drugs face

It was among the first synthetic GH secretagogues and played a central role in establishing that GH release could be stimulated independently of GHRH ultimately contributing to the discovery of the ghrelin receptor (GHS-R1a)

Tirzepatide causes gastrointestinal symptoms including nausea, vomiting, diarrhea, and constipation in a substantial percentage of users, particularly during dose escalation phases

BPC-157 & Wound Healing Skin, Burns, Diabetic Ulcers & Fistulas (PMC, 2021) A comprehensive wound healing review published in Frontiers in Pharmacology documented BPC-157s practical applicability across skin wound types incisional, excisional, deep burns, diabetic ulcers, alkali burns, and fistula healing confirming equivalent efficacy regardless of route of application (systemic or local) and across the same dose range

It looks at their involvement in growth hormone release, hormonal pathways, and downstream effects such as IGF-1 elevation, prolactin regulation, and nitric oxide production

Research shows that ongoing GLP-1 receptor stimulation quickly leads to tachyphylaxis of gastric emptying effects [24]